Detalhe da pesquisa
1.
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
J Immunother Cancer
; 12(2)2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38346853